- Albireo Pharma Inc ALBO entered into a royalties monetization agreement with Sagard Healthcare Partners $115 million in exchange for a mid-single-digit average royalty on Bylvay’s worldwide annual net income.
- Bylvay (Odevixibat) is the first drug approved in the US for pruritus in patients 3 months and older with all progressive familial intrahepatic cholestasis (PFIC).
- In the US and Europe, Bylvay has orphan exclusivity for its approved PFIC indications and orphan status for Alagille syndrome, biliary atresia and primary biliary cholangitis.
- Bylvay is being studied in the open-label PEDFIC 2 study in patients with PFIC, in the phase 3 BOLD study in biliary atresia, and in the phase 3 ASSERT study in ALGS.
- “With this agreement, we significantly strengthen our balance sheet, provide flexibility and extend our cash runway at least beyond the topline data read of our BOLD study in biliary atresia in 2024,” said Ron Cooper, President and Chief Executive Officer of Albireo.
- “These additional resources allow us to grow Bylvay into a billion dollar product and to advance the development of our early asset pipeline.”
- Last year, Albireo sold its Priority Review Voucher (PRV) related to Bylvay, for $105 million.
- Price promotion: ALBO shares are up 14.90% to $19.94 on the last check Thursday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story